Citywire for Financial Professionals

Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

2506.00

Share Price

2510.00

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 98.29%
Worldwide Healthcare (Ordinary Share) NAV 85.61%
FTSE World 56.00%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 2519.0 0.5% 2506.00 2505.00
27 Jun
111% 0.89%

Discrete performance % over

Fund / BenchmarkJul '14
Jun '15
Jul '15
Jun '16
Jul '16
Jun '17
Worldwide Healthcare (Ordinary Share) Price47.41-7.8145.91
Worldwide Healthcare (Ordinary Share) NAV47.65-0.8226.74
FTSE World11.928.8228.09

Discrete performance over

Discrete Performance

Top 10 Holdings

Wright Medical Group, Inc. 5.23%
Merck & Co. Inc. 4.32%
Boston Scientific, Inc. 4.32%
Biogen Idec Inc., 3.72%
Eli Lilly & Co. 3.72%
Alexion Pharmaceuticals, Inc. 3.72%
Regeneron Pharmaceuticals, Inc. 3.42%
HCA Holdings Inc 3.22%
Incyte Corporation 3.22%
Roche Holding AG 3.22%

Sectors weighting

Pharmaceuticals 99.50%
Net Current Assets 0.50%

Regional weighting

North America Region 70.00%
Europe Developed ex-UK 15.00%
Japan 7.00%
Other Countries 4.00%
Asia exc Japan 4.00%
Cash/Cash Equivalent 1.00%
UK 0.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price 2510.00
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 47
  • Market Capital (£M) 1173.63
  • Gross Assets (£M) 1295.67
  • Net Assets (£M) 1167.54
  • TER (%) 0.90
  • Historic Dividend Yield (%) 0.89
  • Last AGM 21 Sep 2016
  • Next AGM 21 Sep 2017
  • Last Annual Report Date 24 Jun 2016
  • Next due Report Date 31 Mar 2017
  • Next due Report Type A/R
  • Objective:

  • To achieve a high level of capital growth by investing worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Samuel Isaly Start: 28 Apr 1995
  • Sven Borho Start: 01 Feb 2013
  • Trevor M. Polischuk Start: 31 Mar 2015
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, plus a fixed amount equal to £ 57,500 p.a. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.

Sorry, this link is not
quite ready yet